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KEY POINTS 
• In a prespecified analysis of the PIVOTAL randomized control trial, proactive 
intravenous iron dosing was not associated with increased stroke risk in 
patients requiring hemodialysis 
• Risk factors for stroke during the trial were consistent with known risk factors 
for vascular events in this patient group including diabetes, history of prior 
stroke, higher baseline systolic blood pressure, lower serum albumin, higher 
C-reactive protein as well as female gender  
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ABSTRACT  
Background People with kidney failure treated with hemodialysis (HD) are at 
increased risk of stroke compared to similarly aged people with normal kidney function. 
One concern is that treatment of renal anemia might increase stroke risk. We studied 
risk factors for stroke in a prespecified secondary analysis of a randomized controlled 
trial of intravenous iron treatment strategies in HD.  
Methods We analyzed data from the Proactive IV IrOn Therapy in HaemodiALysis 
Patients (PIVOTAL) trial focusing on variables associated with risk of stroke. The trial 
randomized 2,141 adults, who had started hemodialysis <12 months earlier and who 
were receiving an erythropoiesis-stimulating agent (ESA), to high-dose IV iron 
administered proactively or low-dose IV iron administered reactively in a 1:1 ratio. 
Possible stroke events were independently adjudicated. We performed analyses to 
identify variables associated with stroke during follow-up and assessed survival 
following stroke.  
Results During a median 2.1 years follow-up, 69 (3.2%) patients experienced a first 
post randomization stroke. 57 (82.6%) were ischemic strokes and 12 (17.4%) 
hemorrhagic strokes. There were 34 post randomization strokes in the proactive arm 
and 35 in the reactive arm (hazard ratio (95% confidence interval): 0.90 (0.56, 1.44), 
p=0.66). In multivariable models, female gender, diabetes, history of prior stroke at 
baseline, higher baseline systolic blood pressure, lower serum albumin and higher C-
reactive protein were independently associated with stroke events during follow up. 
Hemoglobin, total iron or ESA dose were not associated with risk of stroke. 58% of 
patients with a stroke event died during follow-up, compared to 23% without a stroke. 
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Conclusions In hemodialysis patients, stroke risk is broadly associated with risk 
factors previously described to increase cardiovascular risk in this population. 




The estimated increased risk of stroke in patients treated with hemodialysis 
(HD) is approximately two to ten times higher than that the risk of otherwise similarly 
age-matched patients from the general population with greatest excess risk in younger 
people1-4. The prevalence of ‘conventional’ risk factors associated with increased 
stroke risk such as hypertension, diabetes, older age, prior cardiovascular disease, 
and atrial fibrillation is high in patients treated with HD5. Other factors specific to HD 
treatment such as variation in blood pressure and altered cerebral blood flow during 
dialysis may increase stroke risk6.  
Several randomized controlled trials (RCTs) have assessed the effect of 
correction of anemia with erythropoiesis-stimulating agents (ESA) on both surrogate 
parameters, such as left ventricular hypertrophy, and clinical outcomes such as 
cardiovascular events or need for dialysis in patients in patients with chronic kidney 
disease (CKD) or heart failure7-10. The overall effect of anemia correction on stroke 
risk in subjects with CKD has been variable with some trials demonstrating no excess 
stroke risk in the ESA treatment or higher hemoglobin group8, 9, 11. However, in two of 
the largest placebo controlled RCTs of anemia correction in patients with CKD with 
the ESA darbepoetin7, 12, 13, stroke risk was elevated in the group randomized to 
darbepoetin to target a higher hemoglobin. This observation was statistically 
significant in the TREAT trial in patients with diabetes and CKD and in the subgroup 
of patients with CKD in the RED-HF trial suggesting that anemia correction with ESA 
is associated with increased risk of stroke in patients at high vascular risk and CKD 
irrespective of other risk factors for stroke7, 13. However, the effect of anemia correction 
using high iron-dosing strategies (to minimize ESA use) on future stroke risk in patients 
treated with HD is unknown.  
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The PIVOTAL trial was a RCT of proactive versus reactive intravenous iron 
therapy in patients requiring HD already treated with an ESA. The methods, baseline 
characteristics of the participants14 and main trial results15 have been reported 
elsewhere. Briefly, a high-dose proactive intravenous iron regimen resulted in lower 
doses of erythropoiesis-stimulating agent being administered when compared with a 
low-dose iron regimen, with fewer cardiovascular events occurring in the proactive 
arm of the trial. In this pre-specified analysis, we analyzed which factors were 
associated with risk of stroke. We hypothesized that proactive high-dose iron would 
not be associated with increased stroke risk compared to reactive low-dose iron.  
 
MATERIALS AND METHODS 
The design, baseline characteristics11 and main results of PIVOTAL are 
published14, 15. In summary, 2141 adults who had started HD within the previous year, 
who had a ferritin concentration <400 μg per liter and a transferrin saturation <30%, 
and who were receiving an ESA were enrolled. The PIVOTAL trial was being 
conducted in compliance with the principles of the Declaration of Helsinki (1996). The 
study protocol was approved by the South East Coast – Brighton and Sussex 
Research Ethics Committee, and the Medicines and Healthcare products Regulatory 
Agency and registered at EU Clinical Trials register (EudraCT Number: 2013-002267-
25). All patients provided written informed consent. 
Patients were randomized 1:1 to receive high-dose IV iron administered 
proactively or low-dose IV iron administered reactively. Ferritin concentration and 
transferrin saturation were measured monthly, and the results used to determine the 
monthly dose of iron sucrose. In the high-dose group, 400 mg of iron sucrose was 
prescribed, with safety cut-off limits (ferritin >700 μg per liter or transferrin saturation 
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>40%) above which further iron was withheld until the next blood test one month later. 
Patients in the low-dose group received 0 mg to 400 mg of iron sucrose monthly to 
maintain ferritin ≥200 μg per liter and transferrin saturation ≥20%, in line with current 
guidelines. The protocol required the use of an ESA in a dose sufficient to maintain 
hemoglobin between 100 and 120 g per liter, but otherwise patients were treated 
according to usual practice. Blood pressure was recorded at the dialysis unit taken by 
the dialysis unit nursing staff. Investigators were asked to report cardiovascular 
comorbidities at baseline on an electronic case-report form.   
 
Clinical outcomes 
The primary outcome of the trial was the composite of myocardial infarction, 
stroke, hospitalization for heart failure, or death from any cause, analyzed as time-to-
first event. Stroke was a pre-specified secondary outcome. For this manuscript, the 
outcomes of time-to-first stroke are reported. We also analyzed recurrent stroke 
events, to account for the cumulative burden of events over time. Finally, we examined 
mortality related to (initially) non-fatal stroke.   
 
Adjudication of stroke events and outcomes: 
All potential endpoints and all deaths were adjudicated by an independent 
committee, blinded to treatment allocation. Stroke was defined as an acute episode of 
neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular 




Statistical analysis: The time-to-first-event analyses were performed in the intention-
to-treat population using Cox proportional hazards regression. All analyses by 
treatment group allocation were adjusted for the stratification variables of vascular 
access, diabetes, and time on dialysis. The strategy adopted was to fit a multivariable 
Cox regression model for the time to first event of fatal or non-fatal stroke, fitting only 
potential baseline risk factors omitting laboratory variables. From this model we 
identified the four factors (diabetes, SBP, gender and history of stroke) that had 
evidence of association with outcome (p<0.05). The four baseline non-lab risk factors 
were carried forward for inclusion in models with lab variables (loge (CRP), albumin, 
Hb) and ESA dose. A further model was fitted with the subset of variable showing 
evidence of association with outcome (p<0.05). 
The Kaplan–Meier method was used to estimate mortality rates and cumulative 
incidence functions for stroke as a time to first event correcting for the competing risk 
of deaths not included in the outcome of interest. Deaths following a stroke are 
analyzed descriptively. Recurrent events were analyzed using the proportional-means 
model of Lin et al16. Baseline characteristics were summary counts and percentages.  
P-values for between group differences based on chi-squared tests/Fishers exact 
tests, as appropriate, are provided.  Analyses were performed using SAS software, 




Baseline characteristics of patients experiencing stroke  
The PIVOTAL trial randomized 2141 patients of which 1093 patients were 
allocated to the proactive high-dose group and 1048 to the reactive low-dose group. 
The main trial results have been presented elsewhere – to summarize, 320 patients 
(29.3%) in the high-dose group had a primary end-point event, compared with 338 
(32.3%) in the low-dose group (hazard ratio, 0.85; 95% CI, 0.73 to 1.00; P<0.001 for 
noninferiority; P=0.04 for superiority)15. During a median 2.1 years of follow up, 69 
(3.2%) patients experienced a first stroke post randomization. Of these, 57 (82.6%) 
were ischemic strokes and 12 (17.4%) hemorrhagic strokes. Baseline characteristics 
of patients experiencing stroke and those who did not are shown in Table 1. The 
prevalence of diabetes and prior stroke was higher in those who had a stroke during 
follow up. The prevalence of atrial fibrillation was not higher in those who had a stroke.   
Age, BMI, and systolic blood pressure (SBP), and C-reactive protein (CRP) at baseline 
were greater, whilst baseline albumin and hemoglobin were lower in those that had a 
stroke compared to those who did not.  Supplementary Table 1 notes the day of the 
week when the baseline blood pressure was recorded.  
 
Effect of treatment group on stroke incidence 
There were 34 first strokes in the proactive arm and 35 in the reactive arm 
(hazard ratio (95% confidence interval): 0.90 (0.56, 1.44), p=0.66), Figure 1. In a 
recurrent event analysis considering the 10 patients with two stroke events and 1 
patient with three stroke events (total 46 stroke events) in the in the proactive arm and 
the 10 patients with two stroke events and 2 patients with three stroke events (total 49 
events) in the reactive arm, there was no significant difference in stroke incidence 
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between treatment groups (rate ratio (95% confidence interval): 0.88 (0.53, 1.45), 
p=0.61), Table 2.  
 
Factors associated with risk of stroke during the PIVOTAL trial 
In a multivariable Cox regression model analyzing the whole cohort for the time 
to first fatal or non-fatal stroke, fitting only potential baseline risk factors, diabetes, 
SBP, female gender and history of prior stroke were associated with stroke during 
follow up (Table 3). In a further analysis including baseline laboratory variables and 
baseline ESA dose at the start of the trial, diabetes, SBP, female gender and history 
of prior stroke, low serum albumin and elevated logeCRP were independent predictors 
of stroke (Supplementary Table 2). 
In a multivariable analysis taking account of baseline risk factors, with albumin, 
logeCRP, hemoglobin prior to the stroke and the mean iron dose and ESA dose over 
the duration of the trial as time dependent variables, the variables associated with 
stroke were SBP, diabetes, prior stroke, female gender, low serum albumin and 
elevated logeCRP (Table 4).   
 
Outcomes following stroke 
A total of 40 patients (58%) who had a stroke  post randomization subsequently 
died during follow up. This compares to 475 deaths (23%) in the remaining 2072 
patients who did not have a stroke. Of the 40 patients with a first stroke, 3 of the first 
strokes were fatal and one patient died on the same day as the stroke with cause of 
death given as infection. Of the remaining 36 deaths, 14 were non-stroke deaths (none 
within 7 days of the stroke and 1 within 30 days) and 22 were stroke deaths (5 within 
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7 days of the stroke and 12 within 30 days). The Kaplan-Meier time to event curve for 





In the PIVOTAL trial, first stroke events occurred in 69 patients (3.2% of the 
entire cohort), compared to 180 fatal or non-fatal myocardial infarction events (8.4%) 
and 121 (5.7%) hospitalizations for heart failure15. In this large RCTof two different 
strategies for iron replacement in HD patients requiring an ESA as treatment for renal 
anemia, the major independent baseline risk factors for stroke were female gender, 
history of diabetes mellitus or prior stroke, and baseline higher systolic blood pressure. 
On laboratory testing, inflammation (indicated by elevated CRP) and malnutrition 
(indicated by low serum albumin) were associated with increased stroke risk. 
Therefore, in keeping with previous observational data in this population, the major 
risk factors for stroke in PIVOTAL were ‘conventional’ risk factors for stroke observed 
in the general population17, 18. Inflammation and malnutrition have been associated 
with stroke and reduced survival in several observational studies in patients with 
CKD19-21. At baseline, patients who had a post randomization stroke had lower 
hemoglobin than those who did not, although this observation was not statistically 
significant on time to event analyses (Tables 4 and S1). We found no association 
between iron treatment allocation, hemoglobin level, total intravenous iron dose or 
erythropoiesis-stimulating agent dose and stroke risk. This is irrespective of 
hemoglobin rising faster initially (supplementary data of the primary results paper) in 
the proactive treatment arm and patients in the proactive group being significantly less 
likely to receive blood transfusions, presumably because of the initially higher 
hemoglobin level over the first 12 months of the trial15. Some observational registry 
data supports the observation that lower hemoglobin is associated with increased risk 
of stroke in hemodialysis, but this has not been a consistent observation. 1, 22, 23  
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Other RCTs have reported the effect of anemia treatment regimens using ESAs 
in patients with CKD and/or requiring dialysis. In a RCT in incident hemodialysis 
patients, like those studied in PIVOTAL, ‘full’ correction of anemia with epoetin alfa to 
a hemoglobin target of 135-145 g/L compared to a target of 95-115 g/L was associated 
with a significantly higher incidence of stroke (4% vs 1%, p=0.045) over 94 weeks 
follow-up24. In both the placebo-controlled TREAT trial of 4038 patients with diabetes 
and a GFR of 20-60ml/min/1.73m2 randomized to darbepoetin to achieve a 
hemoglobin of 130g/L or placebo, and in the subgroup of 816 patients with diabetes 
and CKD in the RED-HF trial in patients with systolic heart failure using a similar 
placebo-controlled intervention, the higher hemoglobin arm was associated with a 
significantly higher stroke risk (HR for stroke in the darbepoetin group in TREAT was 
1.9; 95% confidence interval, 1.4 –2.7,  HR for stroke  in CKD patients in RED-HF was 
2.07, 95% CI 0.98–4.387, 13). However, in all subjects in the TREAT trial, irrespective 
of treatment allocation, the stroke risk was significantly increased with a lower 
hemoglobin7, 25. By comparison, stroke risk was not significantly greater in the higher 
hemoglobin arm of the Normal Hematocrit study in hemodialysis, nor the CHOIR and 
CREATE studies in patients with non-dialysis CKD, all of which used ESA to target a 
higher hemoglobin but with no placebo in the ‘control’ group8, 9, 11. 
In summary our results provide further reassurance to the headline data of the 
main findings of PIVOTAL, that proactive iron had a neutral effect on stroke events in 
addition to being overall superior to a low-dose iron regime for cardiovascular 
outcomes and lower ESA requirements15. We did not see a relationship between ESA 
dosing in PIVOTAL and risk of stroke. Cumulatively, our results, combined with these 
other data from RCTs, demonstrate that overall a low hemoglobin is associated with 
higher stroke risk in patients with CKD and/or requiring dialysis.   
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Survival after stroke for the dialysis patients in PIVOTAL was poor and 23 
subjects (33.3% of patients with a stroke) had a recurrent stroke event. This is 
consistent with findings of other studies26-28. The overall number of patients with a 
stroke was too small to explore factors that contributed to the poor outcomes of these 
patients. We did not collect data on specific therapies offered to patients in the trial 
who had a stroke. Other observational studies suggest that patients requiring dialysis 
have high functional dependence prior to stroke and hence poor outcome may be 
inevitable26, 29. Perhaps these patients are less likely to receive interventions which 
may improve outcome such as thrombolysis, acute stroke unit care, antiplatelet 
therapy, and associated rehabilitation therapies26, 30. There is a limited evidence-base 
for treatment of stroke in patients requiring dialysis with no data from RCTs specific to 
those on dialysis5, 31. Reduction in kidney function has been demonstrated to be 
associated with poor outcomes following stroke. In post hoc analyses of ENCHANTED 
(Enhanced Control of Hypertension and Thrombolysis Stroke Study) comparing two 
thrombolysis regimes, every 10 mL/min/1.73 m2 lower estimated glomerular filtration 
rate was associated with an adjusted 9% increased odds of death following acute 
ischemic stroke32. Current thrombolysis guidelines suggest that patients with 
advanced CKD including dialysis receive thrombolysis with no specific restrictions 
compared to those with normal kidney function33. Combined National Stroke and 
Renal Registry data from Scotland show people treated with dialysis are less likely to 
be managed on an acute stroke unit following a stroke than the wider stroke population 
(67.4% vs. 79.6%; p < 0.001). Survival after stroke in the same report was significantly 
shorter in those on dialysis (median survival 0.8 years on dialysis compared to  3.1 
years in the non-ESRD stroke population (P < 0.0001))26. The adverse outcomes 
following stroke in PIVOTAL emphasizes the need to identify if poor outcomes are 
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driven by inequalities of care offered26 or an absence of evidence-based therapies for 
acute stroke in this population5, 26, 31. 
There are several limitations to this analysis and further remaining questions 
regarding anemia management in dialysis patients which have not been addressed by 
the PIVOTAL trial. Despite performing a RCT in over 2,000 patients, we observed a 
small number of strokes, although the stoke incidence was similar to other cohort 
studies34, 35. This limits the number of variables that could be tested in multivariable 
analysis. The PIVOTAL trial was not designed to detect differences in stroke outcomes 
between groups. Whilst stroke incidence is relatively high in patients treated with 
dialysis, a RCT specifically targeting stroke as an efficacy end point would be 
challenging. Despite 164 patients (7.6%) having AF at baseline, we captured only 4 
strokes in these patients and cannot comment further on AF as a risk factor for stroke 
in HD. The prevalence of AF was lower than reported in other HD cohorts (10-20%) 
27, 36, 37. As the trial was performed in patients during their first year of hemodialysis, 
the results may not be extrapolated to patients with a longer dialysis history. Longer 
term safety data on the effect of proactive iron on iron overload are required. The 
incidence of stroke at 2.22 per 100 patient years is similar to some reports34, but half 
that in other observational studies in longer term HD patients2, 38. Stroke risk rises over 
the first 90 days after HD commencement and then falls over the next year, prior to 
rising again, so interpreting stroke risk over the first year after commencing HD is 
challenging39. The intravenous iron used in PIVOTAL was iron sucrose. It is unknown 
if similar results would be replicated for a proactive iron dosing strategy if an alternative 
intravenous iron preparations was used. Less than 10% of participants were of Black 
ethnicity, making it challenging to extrapolate the results directly to all ethnic groups. 
This is important given the high incidence of stroke observed in dialysis patients of 
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Black or Hispanic ethnicity in the US38. We only collected baseline blood pressure and 
do not have pre- and post-dialysis blood pressure. Cerebral perfusion drops during 
dialysis which may increase risk of stroke6.  
In conclusion, in a RCT performed in a population at high risk of vascular 
events, we observed no association with high-dose iron and stroke risk despite a 
relatively sharper initial rise in hemoglobin in the proactive iron group15. This contrasts 
with the association with higher hemoglobin and vascular risk seen in the placebo-
controlled anemia correction RCTs in CKD using ESA to drive a higher hemoglobin7, 
13. These observations should provide further reassurance to support the use of a 
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Table 1 Baseline characteristics of patients experiencing stroke and those who did 
not.  Values are number and percentage, mean and standard deviation (±) and median 
and interquartile range as appropriate. Tests of significance are t-test, Mann-Whitney 
U, Chi-squared and Fisher’s exact test as appropriate. Abbreviations, PVD- peripheral 
vascular disease, AV- arteriovenous, SBP - systolic blood pressure, DBP – diastolic 
blood pressure, BMI – body mass index  
Table 2    Incidence of stroke events including both first stroke and recurrent fatal and 
non-fatal stroke events  
Table 3   Baseline clinical variables associated with stroke events during the trial in 
univariable (left) and multivariable models (right) 
Table 4: Association between baseline clinical variables, laboratory data and post 
randomization stroke events in univariable (left) and multivariable models.  
Hemoglobin, ESA and IV iron dose used for this analysis are time varying variables 
based on the  **most recent previous level  or * mean of previous levels over the post 
randomization values for each variable during the trial 
Figure 1 Cumulative incidence of stroke in the proactive (blue) and reactive (red) 
treatment groups accounting for the competing risk of non-stroke deaths.  Between 
group Hazard Ratio (95% confidence interval): 0.90 (0.56, 1.44), p=0.66) 
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 No Stroke Stroke P1 vs 2 Ischemic Hemorrhagic P3 vs 4 
 (1) (2)  (3) (4)  
n 2072  69   57  12   
Statistic Count/ 
mean/ 
med      
%/SD/ 
(LQ,UQ) 
Count/mean/med           %/SD/ 
(LQ,UQ) 










1059 51.1 34 49.28 0.76 30 52.6 4 33.3 0.22 
Gender (% 
male) 
1366 65.9 32 46.4 0.001 24 42.1 8 66.6 0.12 
Ethnicity (% 
white) 
1641 79.2 57 82.61 0.49 48 84.2 9 75.0 0.44 
Age (years) 62.7 ±15.1 65.7 ±13.4 0.074 61.2 ±14.2 66.6 ±13.2 0.24 
SBP (mmHg) 144.3 ±23.5 156.1 ±25.7 <0.001 152.0 ±15.0 157.0 ±27.4 0.38 
DBP (mmHg) 73.6 ±14.8 74.4 ±16.1 0.68 76.3 ±18.5 74.0 ±15.7 0.71 




5.8 3.7 5.0 3.5 0.086 5.2 3.9 5.0 3.4 0.86 
Smoking:   
Current (%) 
240 11.6 9 13.0 0.53 6 10.5 3 25.0 0.33 
                  
Former (%) 
524 25.3 21 25.5  17 29.8 4 33.3  
                  
Never (%) 
1308 63.1 39 62.9  34 59.7 5 41.7  
Diabetes (%) 904 43.6 46 66.7 <0.001 38 66.7 8 66.7 1.00 
Stroke baseline 
(%) 
165 8.0 11 15.9 0.018 10 17.5 1 8.3 0.43 
Myocardial 
infarction (%) 
175 8.5 9 13.0 0.18 8 14.0 1 8.3 0.59 
Heart failure (%) 84 4.1 2 2.9 0.63 1 1.7 1 8.3 na 
Atrial fibrillation 
(%) 
160 7.7 4 5.8 0.55 3 5.3 1 8.3 na 
PVD (%) 182 8.8 5 7.3 0.66 4 7.0 1 8.3 na 
AV fistula/graft 
(%) 
1222 59.0 35 50.7 0.17 32 56.1 3 25.0 0.05 
Primary renal 
disease 
    0.016     na 
Hypertension 
(%) 




677 32.7 35 50.7  28 49.1 7     58.3  
Glomerular 
disease (%) 
386 18.6 8 11.6  7 12.3 1 8.3  
Tubulointerstitial 
disease (%) 
198 9.6 3 4.4  2 3.5 1 8.3  
Renovascular 
disease (%) 




117 5.7 0 0  0 0 0 0  
Other (%) 126 6.1 3 4.4  2 3.5 1 8.3  
Unknown (%) 201 9.7 5 7.3  5 8.8 0 0  
Hemoglobin 
(g/L) 
105.7 ±13.7 100.9 ±12.8 0.003 103.3 ±13.6 100.4 ±12.7 0.52 
Albumin (g/L) 35.8 ±5.1 33.3 ±5.3 <0.001 32.9 ±5.4 35.3 ±4.7 0.13 
logeCRP (mg/L) 1.86 ±1.08 2.30 ±0.98 0.001 2.08 ±0.91 2.34 ±1.00 0.40 
ESA dose 
(IU/week) 
8589 5636 8561 5500 0.97 4917 2314 9328 5678 <0.001 
Mean IV iron 
dose/month 
(mg) 







(n =2141) Proactive (n =1093) 
Reactive  
(n =1048) 
Events per patient    
Patients with 0 events 2072 (96.78%) 1059 (96.89%) 1013 (96.66%) 
Patients with only 1 
event 
46 (2.15%) 23 (2.10%) 23 (2.19%) 
Patients with 2 events  20 (0.93%) 10 (0.91%) 10 (0.95%) 
Patients with 3 events 3 (0.14%) 1 (0.09%) 2 (0.19%) 
Total patients with at 
least 1 stroke 
69 34 35 
Patients with at least 1 
stroke/100 person-
years 
1.62 1.54 1.70 
Total (first and 
recurrent) strokes  
95 46 49 
Total number of strokes 
per 100 person-years 
2.22 2.08 2.38 
 
 
Table 2. Incidence of stroke events including both first stroke and recurrent fatal and 






















Table 3: Baseline clinical variables associated with stroke events during the trial in 
univariable (left) and multivariable models (right) 
 
  
Variable HR (95% CI) p HR (95% CI) p 
Gender (female/male) 2.11 (1.31, 3.40) 0.0022 2.15 (1.34, 3.45) 0.0016 
Diabetes (Yes/No) 2.09 (1.26, 3.47) 0.0042 2.08 (1.25, 3.45) 0.0046 
Stroke (Yes/No) 1.98 (1.03, 3.78) 0.039 2.02 (1.06, 3.85) 0.033 
SBP (per 10 mmHg) 1.18 (1.07, 1.30) 0.0012 1.18 (1.07, 1.30) 0.00090 
Dialysis Vintage duration (per 
month) 0.87 (0.54,1.41) 0.58   
Age (per 5 years) 1.08 (0.98, 1.19) 0.10   
AF (Yes/No) 0.78 (0.28, 2.18) 0.63   
Vascular access (Graft/Fistula/ 
Catheter) 0.78 (0.48, 1.25) 0.30   
Treatment 








Variable HR (95% CI) p HR (95% CI) p 
Gender (female/male) 2.14 (1.33, 3.45) 0.0018 2.15 (1.34, 3.47) 0.0016 
Stroke (Yes/No) 1.98 (1.03, 3.76) 0.040 1.98 (1.04, 3.78) 0.038 
Diabetes (Yes/No) 1.96 (1.18, 3.26) 0.0097 1.96 (1.18, 3.26) 0.0093 
**LogeCRP (per 1 unit) 1.40 (1.13, 1.73) 0.0014 1.42 (1.15, 1.75) 0.0013 
SBP (per 10 mmHg) 1.19 (1.08, 1.31) 0.00060 1.18 (1.08, 1.31) 0.00046 
**Albumin (per 10 units) 0.62 (0.40, 0.95) 0.029 0.59 (0.38, 0.89) 0.013 
**Hemoglobin (per 10 units) 0.92 (0.77, 1.10) 0.35   
*ESA (per 100 units) 1.00 (1.00, 1.00) 0.98   
*IV iron dose (per 100 units) 0.97 (0.81, 1.15) 0.71   
 
 
Table 4: Association between baseline clinical variables, laboratory data and post 
randomization stroke events in univariable (left) and multivariable models.  
Hemoglobin, ESA and IV iron dose used for this analysis are time varying variables 
based on the  **most recent previous level  or * mean of previous levels over the post 










Proactive              1093                            831                            600                           219      33                    
Reactive               1048                            778                            546                           213      22
